136 related articles for article (PubMed ID: 19201069)
1. [Crohn's disease during the course of multiple sclerosis: role of interferon-beta therapy].
Samson M; Audia S; Duchêne C; Perinet I; Bielefeld P; Besancenot JF
Rev Med Interne; 2009 Sep; 30(9):816-9. PubMed ID: 19201069
[TBL] [Abstract][Full Text] [Related]
2. Unmasking of autoimmune hepatitis in a patient with MS following interferon beta therapy.
Pulicken M; Koteish A; DeBusk K; Calabresi PA
Neurology; 2006 Jun; 66(12):1954-5. PubMed ID: 16801674
[No Abstract] [Full Text] [Related]
3. Ischemic colitis with type I interferons used in the treatment of hepatitis C and multiple sclerosis: an evaluation from the food and drug administration adverse event reporting system and review of the literature.
Salk A; Stobaugh DJ; Deepak P; Ehrenpreis ED
Ann Pharmacother; 2013 Apr; 47(4):537-42. PubMed ID: 23535814
[TBL] [Abstract][Full Text] [Related]
4. Panniculitis after subcutaneous injection of interferon beta in a multiple sclerosis patient.
Heinzerling L; Dummer R; Burg G; Schmid-Grendelmeier P
Eur J Dermatol; 2002; 12(2):194-7. PubMed ID: 11872423
[TBL] [Abstract][Full Text] [Related]
5. Retinopathy in a multiple sclerosis patient undergoing interferon-therapy.
Saito H; Suzuki M; Asakawa T; Kato S
Mult Scler; 2007 Aug; 13(7):939-40. PubMed ID: 17468441
[TBL] [Abstract][Full Text] [Related]
6. Full results of the Evidence of Interferon Dose-Response-European North American Comparative Efficacy (EVIDENCE) study: a multicenter, randomized, assessor-blinded comparison of low-dose weekly versus high-dose, high-frequency interferon beta-1a for relapsing multiple sclerosis.
Schwid SR; Panitch HS
Clin Ther; 2007 Sep; 29(9):2031-48. PubMed ID: 18035202
[TBL] [Abstract][Full Text] [Related]
7. Interferon beta in multiple sclerosis: how much BENEFIT?
Pittock SJ
Lancet; 2007 Aug; 370(9585):363-4. PubMed ID: 17678997
[No Abstract] [Full Text] [Related]
8. Genomic effects of once-weekly, intramuscular interferon-beta1a treatment after the first dose and on chronic dosing: Relationships to 5-year clinical outcomes in multiple sclerosis patients.
Weinstock-Guttman B; Bhasi K; Badgett D; Tamaño-Blanco M; Minhas M; Feichter J; Patrick K; Munschauer F; Bakshi R; Ramanathan M
J Neuroimmunol; 2008 Dec; 205(1-2):113-25. PubMed ID: 18950872
[TBL] [Abstract][Full Text] [Related]
9. Lupus erythematosus profundus (lupus panniculitis) induced by interferon-beta in a multiple sclerosis patient.
Gono T; Matsuda M; Shimojima Y; Kaneko K; Murata H; Ikeda S
J Clin Neurosci; 2007 Oct; 14(10):997-1000. PubMed ID: 17669654
[TBL] [Abstract][Full Text] [Related]
10. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG).
Jacobs LD; Cookfair DL; Rudick RA; Herndon RM; Richert JR; Salazar AM; Fischer JS; Goodkin DE; Granger CV; Simon JH; Alam JJ; Bartoszak DM; Bourdette DN; Braiman J; Brownscheidle CM; Coats ME; Cohan SL; Dougherty DS; Kinkel RP; Mass MK; Munschauer FE; Priore RL; Pullicino PM; Scherokman BJ; Whitham RH
Ann Neurol; 1996 Mar; 39(3):285-94. PubMed ID: 8602746
[TBL] [Abstract][Full Text] [Related]
11. Combination therapy with interferon-beta and glatiramer acetate in multiple sclerosis.
Ytterberg C; Johansson S; Andersson M; Olsson D; Link H; Holmqvist LW; von Koch L
Acta Neurol Scand; 2007 Aug; 116(2):96-9. PubMed ID: 17661794
[TBL] [Abstract][Full Text] [Related]
12. Influence of Interferon beta treatment on quality of life in multiple sclerosis patients.
Simone IL; Ceccarelli A; Tortorella C; Bellacosa A; Pellegrini F; Plasmati I; De Caro MF; Lopez M; Girolamo F; Livrea P
Health Qual Life Outcomes; 2006 Dec; 4():96. PubMed ID: 17163989
[TBL] [Abstract][Full Text] [Related]
13. Reversible pulmonary arterial hypertension associated with interferon-beta treatment for multiple sclerosis.
Gibbons E; Promislow S; Davies RA; Chandy G; Stewart DJ; Vladamir CD; Pugliese C; Dunne R; Mielniczuk LM
Can Respir J; 2015; 22(5):263-5. PubMed ID: 26083539
[TBL] [Abstract][Full Text] [Related]
14. Subcutaneous IFN-β1a to treat relapsing-remitting multiple sclerosis.
Thouvenot E; Carlander B; Camu W
Expert Rev Neurother; 2012 Nov; 12(11):1283-91. PubMed ID: 23140228
[TBL] [Abstract][Full Text] [Related]
15. Lobular panniculitis at the site of subcutaneous interferon beta injections for the treatment of multiple sclerosis can histologically mimic pancreatic panniculitis. A study of 12 cases.
Ball NJ; Cowan BJ; Hashimoto SA
J Cutan Pathol; 2009 Mar; 36(3):331-7. PubMed ID: 19032383
[TBL] [Abstract][Full Text] [Related]
16. Severe local skin reactions to interferon beta-1b in multiple sclerosis-improvement by deep subcutaneous injection.
Nakamura Y; Kawachi Y; Furuta J; Otsuka F
Eur J Dermatol; 2008; 18(5):579-82. PubMed ID: 18693165
[TBL] [Abstract][Full Text] [Related]
17. Arthritis and bursitis in multiple sclerosis patients treated with interferon-beta.
Strueby L; Nair B; Kirk A; Taylor-Gjevre RM
Scand J Rheumatol; 2005; 34(6):485-8. PubMed ID: 16393774
[TBL] [Abstract][Full Text] [Related]
18. [The interferon beta therapy after the first clinical episode of demyelination in multiple sclerosis].
Demina TL; Khachanova NV; Davydovskaia MV
Zh Nevrol Psikhiatr Im S S Korsakova; 2006; 106(3):15-9. PubMed ID: 16608106
[TBL] [Abstract][Full Text] [Related]
19. Characteristics associated with drug-induced liver injury from interferon beta in multiple sclerosis patients.
Kowalec K; Kingwell E; Yoshida EM; Marrie RA; Kremenchutzky M; Campbell TL; Wadelius M; Carleton B; Tremlett H
Expert Opin Drug Saf; 2014 Oct; 13(10):1305-17. PubMed ID: 25134421
[TBL] [Abstract][Full Text] [Related]
20. [Interferon therapy of multiple sclerosis. Synopsis of various dosage forms].
Jarius S; Hohlfeld R
Nervenarzt; 2004 Dec; 75(12):1226-30. PubMed ID: 15565383
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
